Advertisement
Organisation › Details
Humabs BioMed S.A.
Humabs BioMed, a private biotechnology company based in Switzerland, is focused on discovering and developing fully human monoclonal antibodies to treat serious infections. Humabs BioMed is a spin-off of the Institute for Research in Biomedicine (IRB), which is affiliated with the Universita` della Svizzera Italiana (USI). Humabs' proprietary discovery technology - CellClone - platforms enable the isolation of antibodies that have passed natural selection by the human immune system in response to disease and can generally be developed rapidly without extensive lead optimization. Humabs has a portfolio of more than a dozen immunotherapy product candidates. The Company has partnered several of its programs with MedImmune and Novartis, and two of these programs are now in clinical development by these partners. Humabs is internally developing antibodies directed against hepatitis B virus and respiratory syncytial virus and metapneumovirus (RSV/MPV). These programs are currently in preclinical development. In collaboration with various public health agencies, Humabs is also developing a portfolio of immunotherapies against major public health threats, including MERS-CoV, dengue, Ebola, Rabies and Zika viruses. *
Start | 2017-07-18 existent | |
Group | Vir Biotechnology (Group) | |
Industry | therapeutic antibody | |
Industry 2 | virostatic agent | |
Region | Switzerland_oo | |
Country | Switzerland | |
Street | 1 Via Mirasole | |
City | 6500 Bellinzona | |
Tel | +41-91-825-6380 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Humabs BioMed S.A.. (7/18/17). "Press Release: Humabs BioMed and University of California, Berkeley Announce Publication of Data for Novel Antibody-based Assay to Detect Zika Virus Infection". Bellinzona & Berkeley, CA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Vir Biotechnology (Group)
- [1] GlaxoSmithKline plc. (4/6/20). "Press Release: GSK and Vir Biotechnology Enter Collaboration to Find Coronavirus Solutions". London & San Francisco, CA....
- [2] Vir Biotechnology, Inc.. (10/18/17). "Press Release: Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious Diseases". San Francisco, CA....
- [3] Humabs BioMed S.A.. (9/21/17). "Press Release: Data on Novel Bi-specific Antibody to Treat Zika Virus Infection Published in »Cell«"....
- [4] Humabs BioMed S.A.. (7/18/17). "Press Release: Humabs BioMed and University of California, Berkeley Announce Publication of Data for Novel Antibody-based Assay to Detect Zika Virus Infection". Bellinzona & Berkeley, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top